Поисковый запрос: <.>S=ПЛАЗМИНОГЕНА АКТИВАТОР ТКАНЕВОГО ТИПА -- TISSUE PLASMINOGEN ACTIVATOR<.> |
Общее количество найденных документов : 38
Показаны документы с 1 по 20 |
|
1.
| Активація протеїну С в процесі тромболізису in vitro/І. І. Паталах [та ін.] // Фізіологічний журнал. -К., 2015. т.Т. 61,N № 4.-С.78-84
|
2.
| Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombus/A.J. Lucking, K.R. Gibson, E.E. Paterson et al. // ARTERIOSCLEROSIS, THROMBOSIS, and VASCULAR BIOLOGY. -Iowa City:Univercity of Iowa, 2013. т.Vol.33,N N5.-С.1105-1111
|
3.
| Герштейн Е. С. Клинические перспективы исследования ассоциированных с опухолью протеаз и их тканевых ингибиторов у онкологических больных/Е. С. Герштейн, Н. Е. Кушлинский // Вестник Российской академии медицинских наук. -М., 2013,N № 5.-С.16-27
|
4.
| Henninger N. Stroke : higlights of selected articles./N. Henninger // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2012. т.Vol.43,N N11.-С.2845
|
5.
| Risk score for intracranial hemorrage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator./B.K. Menon, J.L. Saver, Shyam Prabhakaran et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2012. т.Vol.43,N N9.-С.2293-2299
|
6.
| Low-dose intravenous recombinant tissue-type plasminogen-activator therapy for patients with stroke outside european indications. Stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rtPA registry /Masatoshi Koga, Yoshiaki Shiokawa, Jyoji Nakagawara et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2012. т.Vol.43,N N1.-С.253-255
|
7.
| Predictors of tissue-type plasminogen activator nonresponders according to location of vessel occlusion/N. Mendonca, D. Rodrigues-Luna, M. Rubiera et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2012. т.Vol.43,N N2.-С.417-421
|
8.
| EPITHET. Positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-wighted imaging co-registration /Y. Nagakane, S. Christensen, C. Brekenfeld et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2011. т.Vol.42,N N1.-С.59-64
|
9.
| Кузнецов Д.Н. Клиническая эффективность тромболитической терапии препаратом алтеплаза и двойной антитромбоцитарной терапии при остром инфаркте миокарда/Д.Н. Кузнецов, В.В. Трусов, И.А. Казакова // Кардиоваскулярная терапия и профилактика. -М, 2011. т.Том10,N N6.-С.59-63
|
10.
| Early changes of tissue perfusion after tissue plasminogen activator in hyperacute ischemic stroke/H. An, A.L. Ford, K. Vo et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2011. т.Vol.42,N N1.-С.65-72
|
11.
| Outcome by stroke etiology in patients receiving thrombolytic treatment/S. Mustanoja, A. Meretoja, J. Rutaala et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2011. т.Vol.42,N N1.-С.102-106
|
12.
| Effect of baseline CT scan appearance and time to recanalization on clinical outcomes in endovascular thrombectomy of acute ischemic strokes/M. Goyal, B.K. Menon, S.B. Coutts et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2011. т.Vol.42,N N1.-С.93-97
|
13.
| The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the echoplanar imaging thrombolytic evaluation trial (EPITHET)/D. De Silva, C. Brekenfeld, M. Ebinger et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2010. т.Vol.41,N N2.-С.295-299
|
14.
| Safety and efficacy of ultrasound-enhanced thrombolysis/G. Tsivgoulis, J. Eggers, M. Ribo et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2010. т.Vol.41,N N2.-С.280-287
|
15.
| Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale/M.G. Lansberg, M. Schrooten, E. Bluhmki et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2009. т.Vol.40,N N6.-С.2079-2084
|
16.
| Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender/E. Meseguer, M. Mazighi, J. Labreuche et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2009. т.Vol.40,N N6.-С.2104-2110
|
17.
| Granulocyte-colony stimulating factor delays PWI/DWI mismatch evolution and reduces final infarct volume in permanent-suture and embolic focal cerebral ischemia models in the ret/B.T. Bratane, J. Bouley, A. Schneider et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2009. т.Vol.40,N N9.-С.3102-3106
|
18.
| M1 susceptibility vessel sign on T2 as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke/K. Kimura, Y. Iguchi, K. Shibazaki et al. // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2009. т.Vol.40,N N9.-С.3130-3132
|
19.
| Davis S.M. 4,5 hours/S.M. Davis, G.A. Donnan // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2009. т.Vol.40,N N6.-С.2266-2267
|
20.
| Minocycline and tissue-type plasminogen activator for stroke/L.S. Machado, I.Y. Sazonova, A. Kozak, D.C. Wiley // STROKE. -Philadelphia:Lippincott Williams and Wilkins, 2009. т.Vol.40,N N9.-С.3028-3033
|
|
|
|
Періодичних видань
Стандартный